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Short Communication
Evaluation of a rosetting method in detection of breast
cancer cells
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Epithelial membrane antigen (EMA) (Heyderman et
al., 1979) is a membrane component expressed by
most epithelial cells, by all breast carcinomas and
their metastases but not by the vast majority of
normal bone marrow cells (Sloane et al., 1980). It
has been shown that immunocytochemical staining
for EMA can detect very small numbers of breast
cancer in bone marrow smears that appear normal
by conventional haematological techniques
(Dearnaley et al., 1981).
However, because bone marrow infiltration by
breast cancer is patchy involving some sites and not
others (Brunning et al., 1975), we have found that
aspirates must be taken from multiple sites to avoid
sampling error. The examination of such large-
volume samples is time-consuming because of the
number of smears produced and we therefore
sought a process to concentrate the malignant cells.
This paper describes a rosetting technique
utilising a monoclonal antibody (anti-HLe-l) which
recognises an antigen present on almost all normal
narrow cells but not on an any malignant or
epithelial cells (Beverley, 1980). Using this antibody
to form rosettes 95-98% of marrow cells can be
removed producing a smaller number of smears.
We have compared the rosetting technique with
density separation over lymphoprep previously
described (Dearnaley et al., 1981).
The standard method, hereafter referred to as
"the density method", currently in use for
preparation of marrow samples for EMA staining
consists of removal of erythrocytes and mature
granulocytes by centrifugation over Ficoll-Hypaque
of density 1.007 (lymphoprep). Marrow samples
were layered over lymphoprep and centrifuged at
400g for 20min. The cells retained at the interface
were then aspirated, and pelleted. The pellet was
resuspended in a small volume of sterile PBS and
transferred to a siliconised 1 ml conical tip
polypropylene tube. The cells were pelleted,
transferred to the microscope slides and smeared.
The smears were then immediately wet-fixed in
100% ethanol for 2 h.
Human erythrocytes (RBC) were coupled by
chromium chloride to sheep anti-mouse Ig (SaM).
The coupled erythrocytes (RBC.SaM) were added
to the marrow samples previously incubated with
mouse monoclonal anti-HLe-1. Rosettes formed
around any cell bearing mouse Ig allowing density
separation of the rosette-forming (i.e. normal
marrow) cells. Chromium chloride was prepared by
the "ageing" method (Goding, 1976). Briefly a 1%
solution of chromium chloride (CrCl3) in 0.9%
sodium chloride (NaCl) was adjusted to pH 5 by
the addition of 1 N sodium hydroxide twice-weekly
for 3 weeks, then stored without further adjustment
in a dark container. A 0.1% solution in 0.9% NaCl
was prepared freshly from this stock just prior to
use. Erythrocytes from fresh heparinised blood
taken from healthy volunteers were washed 4 x in
0.9% saline, and then pelleted. An aliquot of 85 p1
of the packed RBC pellet was then resuspended in
a suitable volume of 0.9% saline so that when the
SaM and the CrCl3 were added the resulting
volume was 2ml. The antibody used was a hetero-
antiserum sheep-anti-mouse-immunoglobulin (SaM)
dialysed extensively against 0.9% NaCl. An aliquot
(0.5mg) of this antibody was added and followed
immediately by 135pl of fresh 0.1% CrCl3. After
5min at room temperature with occasional
agitation, the reaction was quenched with 3-5ml of
PBS, and red cells were washed twice in PBS and
resuspended in 5ml of medium. The red cells now
coupled to SaM (RBC.SaM) were stored on ice
overnight for use within 24h.
The monoclonal antibody anti-HLe-I was kindly
provided as culture supernatant by Dr P.C.L.
Beverley of the ICRF Tumour Immunology Unit,
University College, London. This antibody
recognises an antigen present to some degree on all
lymphoid and myeloid cells in the marrow but not
late normoblasts (Beverley, 1980). Studies using
cell-lines and human tissues had shown no cross-
reactivity with breast cancer or other epithelial
tissues (Beverley, 1980). The supernatant was used
at a final dilution of 1:50.
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The rosetting method used was based on that
of Parish & McKenzie (1978). The marrow sample,
up to a total of 8 x 107 nucleated cells per universal
container was incubated with anti-HLe-I at 1:50
dilution for 1h at room temperature and then
washed twice in tissue culture medium (RPMl 1640,
HEPES buffered, with 2% foetal calf serum). To
each container 2ml of the previously prepared
RBC.SaM was added. In order to encourage rosette
formation the marrow cells and RBC.SaM were
compressed onto a Percoll cushion. It was found
that this made resuspension of the formed rosettes
easier and caused less loss of viability than using
centrifugation at low gravity onto the bottom of
the container. The cushion was formed by
underlaying 2ml of isotonic Percoll (prepared with
9vol of neat Percoll to vol of 1Ox PBS) beneath
the mixture using a long needle. The mixture was
then centrifuged at 200g for 5min and then left at
unit gravity for 10min. The Percoll cushion was
then carefully withdrawn from beneath the mixture
which was then ready for separation.
Control experiments using leukocytes that had
not been incubated with anti-HLe-I showed that
RBC.SaM did not form spontaneous rosettes
around human leukocytes. Trypan blue
preparations of rosetted marrow cells showed that
rosettes were formed comprising 50-200 red cells
per leukocyte.
In order to minimise non-specific loss of
malignant cells into the pellet during separation of
rosette-forming (marrow) cells, a higher density of
Ficoll-Hypaque was used. Ficoll-Hypaque of
density 1.100 was prepared by mixing 37ml of
lymphoprep with 15ml of sodium diatrizoate
(Hypaque). The density of random batches was
checked with a 1Oml density bottle.
The marrow aspirate/RBC.SaM mixture, after
removal of the Percoll cushion, was gently
resuspended by inverting the tube 3 times. Then
10ml of Ficoll-Hypaque of density 1.100 was
underlayered. The samples were then centrifuged at
400g for 20min. The cells retained at the interface
were then prepared for staining in the same way as
those in the density method.
Immunocytochemical staining for EMA has
already been described (Dearnaley et al., 1981).
Briefly, the endogenous alkaline phosphatase
activity of osteoblasts was blocked by periodic acid,
acetic acid and levamisole and the cells incubated
with rabbit anti-EMA at 1:1000 dilution. After
washing they were incubated with goat-anti-rabbit-
immunoglobulin conjugated to alkaline phosphatase
and the colour reaction developed by using
Naphthol AS:Bl and Brentamine Fast Red TR to
produce a red stain on all cells expressing EMA.
Counterstaining was with Meyer's haemalum.
In order to find out whether the rosetting
technique, in concentrating the marrow aspirates,
removed significant numbers of malignant cells,
two series of experiments were carried out: (i)
Large volume single (10-15ml) aspirates were taken
from 20 consenting patients known to have bone
involvement on bone scan or skeletal survey. The
samples were divided into equal aliquots, one being
prepared by the density method, the other by the
rosetting method. (ii) In a further series of 46
patients with biopsy proven breast cancer, having a
general anaesthetic for some other purpose (e.g.
mastectomy, oophorectomy), marrow samples were
aspirated from 8 sites (from bilateral anterior and
posterior iliac spine from the upper and lower
sternum and from 2 sacral sites). Theses samples
were divided into equal aliquots in all but 9
experiments (where only one third of the sample
was processed by the rosetting technique).
Table I shows that the rosetting technique
removed an average of 97.3% and 94.2% of the
marrow cells from the 26 single aspirates and 46
multiple aspirates respectively.
The density method produced an average of 5
smears in the single and 20 smears in the multiple
aspirates series. The rosetting technique yielded an
average of 2 smears in both series, representing a
Table I Efficiency of rosetting in both series ofmarrow aspirates
Average Marrow
volwne cells
Of rosetted No. ofsmears
sample No. ofmarrow out produced by
rosetted cells at start (%) density method
Multiple 7.1 ml 6.8 x 107 94.2 26
aspirates (3-19 x 107) (85-99.1) (18-41)
(46 patients)
Single 6.1 ml 4.3 x 107 97.3 5
aspirate (1.2-18.7 x 107) (84-99.9) (1-27)
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considerable reduction in the number of slides
screened.
Table II compares the number of positive
samples detected by the two methods. The rosette
method produced a false negative result in 11
patients in whom malignant cells were detected by
the density method and did not yield any positive
samples when the density method was negative.
Table II Comparison of density method
and rosette method results






Total number compared 66
From Figure 1 it can be seen that the rosetting
technique produced a negative result when there
were only small numbers of malignant cells present
(<6 cells). However, when larger numbers of cells
were present both the rosetting and the density
method yielded positive results.
Table III compares the results of the density
method with the clinical status of the patients. It
can be seen that 20% of patients with primary
breast cancer with no evidence of metastases had
demonstrable malignant cells in their marrow by
analysis of multiple aspirates using the density
method. Eighty percent of patients with known
bony metastases in the single aspirate series and
75% of patients with other metastases in the
multiple aspirate series had positive samples.
Table III Number of positive samples in series of




Primary breast 8/39 (20)
cancer
Known evidence 1/3 (33) 16/20 (80)
of bone
metastases












































Figure 1 Results of the rosetting technique in all
samples in which malignant cells were detected by the
density method.
The negative rosetting technique described here
clearly offers a highly selective method of removing
haematological cells from a cell suspension or
marrow sample. Unfortunately, it may be of limited
value in the early detection of metastatic spread of
breast cancer to bone marrow since when 6 or less
malignant cells are present in the sample, they are
likely to be lost into the pellet instead of being
retained at the interface.
The rosetting rechnique was devised in order to
minimise the problem of non-specific nucleated cell
loss, and the high density separation medium FH
1.100 is the highest density that will allow
separation or erythrocytes so that further
improvement or resolution of the problem is not
likely with this technique.
From the clinical point of view, the significance
of any malignant cells in the marrow can only be
defined after long-term follow-up of these patients.
Since there are no data to suggest any clinically
significant "threshold" for malignant cells in the
marrow, we felt that it would not be advisable to
- - - - - - -
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miss lower (i.e. <6) numbers of malignant cells.
Therefore the rosetting technique is unsuitable for
use on a routine basis for the clinical staging of
patients with breast cancer.
However, there are other tumours in which it
would be greatly desirable to detect early invasion
of the bone marrow. This technique may be more
suitable for tumours such as small cell carcinoma of
the lung (SCCL) where the number of cells found
in marrow is generally higher and where marrow
involvement is more commonly detected by
conventional staining. At the time of writing, there
are no exceptionally useful monoclonal antibodies
raised for the identifying metastatic cells from
SCCL. However, workers at two centres are active
in this field and both are planning to use the anti-
HLe-1 rosetting technique to look for small
numbers of malignant cells in patients with SCCL
and apparently limited disease. Provided the cell
numbers are larger than in breast cancer, the
technique may be of value.
Negative rosetting may also have a role in the
selective removal of leukocytes from cell mixtures.
It has been used in this way to produce pure
tumour cell populations from digests of metastatic
lymph nodes and has enabled us to study cell
surface antigens of pure human tumour cell
populations.
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